News - Liminal BioSciences will be presenting at EASL Congress 2026 (27–30 May) in Barcelona

Pipeline

Global
Rights
Program
Potential
Indications
Preclinical
Discovery
Lead Optimisation
CTA-enabling
Clinical
Phase 1
Phase 2
Phase 3
Expected Milestones
GPR84 Antagonist
  • Metabolic Disease/MASH/NAFLD

Phase 1b/2a clinical trial in progress

OXER1 Antagonist
  • Eosinophilic-Driven Asthma

Preclinical candidate nominated

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.